Brazil
  • pt
  • en
    • Search

    GNOM

    Genomics & Biotechnology ETF

    Invest in GNOM

    Reasons to Consider GNOM

    High Growth Potential

    Manufacturing genomic medicines is cumbersome, but new techniques using donated cells are more scalable and could slash production costs by 95%, potentially facilitating broader adoption.1

    Structural Tailwinds

    Recent regulatory approvals have helped genomic medicines gain momentum. Sales of genomic medicines are forecast to increase at a 39% compound annual growth rate from 2024-2030.2

    Targeted Exposure

    GNOM provides global exposure to emerging areas within the Health Care sector, at the intersection of science and technology.

    1International Society for Cell and Gene Therapy, Feb 2019
    2Evaluate Pharma, n.d., Technology Overviews of: Cell Therapy, Gene Therapy, Gene-Modified Cell Therapy, and Genome Editing, all accessed 1 Nov 2024

    Key Information As of 06/25/25

    Inception Date 04/05/19
    Total Expense Ratio 0.50%
    Net Assets $44.18 million
    NAV $8.37

    ETF Summary

    The Global X Genomics & Biotechnology ETF (GNOM) seeks to invest in companies that potentially stand to benefit from further advances in the field of genomic science, such as companies involved in gene editing, genomic sequencing, genetic medicine/therapy, computational genomics, and biotechnology.

    ETF Objective

    The Global X Genomics & Biotechnology ETF (GNOM) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Solactive Genomics Index.

    Trading Details As of 06/25/25

    Ticker GNOM
    B3 Trading Code BGNO39
    Bloomberg Index Ticker SOLGNOM
    CUSIP 37954Y434
    ISIN US37954Y4347
    Primary Exchange Nasdaq
    Shares Outstanding 5,280,000
    Number of Holdings 51
    30-Day Median Bid-Ask Spread 0.13%

    Distributions As of 06/25/25

    30-Day SEC Yield -0.04%
    Distribution Frequency Semi-Annually
     Distribution History

    ETF Prices As of 06/25/25

    NAV $8.37 Daily Change -$0.01 -0.12%
    Market Price $8.36 Daily Change -$0.03 -0.36%

    Performance History

    Premium Discount Chart
    Cumulative Returns (as of 05/30/25)
    		1 Month 6 Months YTD 12 Months 24 Months Since Inception Inception Date
    Return GNOM -5.24% -28.26% -19.90% -23.60% -36.29% -49.06% 04/05/19
    Returns (as of 06/25/25)
    		Return GNOM Return Index
    Since Inception -45.13% -43.39%
    12 Months -19.98% -19.61%
    24 Months -30.80% -29.88%
    Last 60 Trading Days 0.25% 0.23%
    Last 75 Trading Days -8.42% -8.36%
    Monthly Returns (through 06/25/25)
    		Return GNOM Return Index
    Jun 2025 7.72% 7.75%
    May 2025 -5.24% -5.25%
    Apr 2025 2.14% 2.06%
    Mar 2025 -13.01% -12.97%
    Feb 2025 -9.25% -9.20%
    Jan 2025 4.84% 4.87%
    Dec 2024 -10.43% -10.37%
    Nov 2024 4.53% 4.55%
    Oct 2024 -7.83% -7.80%
    Sep 2024 -1.42% -1.26%
    Aug 2024 -1.88% -1.86%
    Jul 2024 11.10% 11.20%
    Jun 2024 2.86% 2.88%
    May 2024 3.26% 3.28%
    Apr 2024 -13.27% -13.23%
    Mar 2024 -5.41% -5.20%
    Feb 2024 11.62% 11.55%
    Jan 2024 -7.01% -6.90%
    Dec 2023 11.12% 11.12%
    Nov 2023 17.53% 17.71%
    Oct 2023 -12.70% -12.66%
    Sep 2023 -9.53% -9.44%
    Aug 2023 -8.41% -8.28%
    Jul 2023 1.22% 1.27%
    Jun 2023 -0.83% -0.71%

    Total returns take into account management, administration and fees and other costs automatically deducted from the fund's assets. Before investing, you may read the prospectus in the “FEES AND EXPENSES” section for more details.

    NAV & Index Chart

    Top Holdings As of 06/25/25

    Full Holdings (.csv)
    Net Assets (%) Ticker Name Country SEDOL Market Price ($) Shares Held Market Value ($)
    5.26 ALNY ALNYLAM PHARMACE United States B00FWN1 321.94 7,221 2,324,728.74
    4.89 CRSP CRISPR THERAPEUTICS AG United States BDHF4K6 47.66 45,334 2,160,618.44
    4.84 ILMN ILLUMINA INC United States 2613990 93.23 22,914 2,136,272.22
    4.43 QGEN QIAGEN N.V. United States BS2CPH1 47.45 41,285 1,958,973.25
    4.37 NTRA NATERA INC United States BYQRG48 164.16 11,761 1,930,685.76
    4.32 GH GUARDANT HEALTH INC United States BFXC911 49.90 38,282 1,910,271.80
    4.09 TECH BIO-TECHNE CORP United States BSHZ3Q0 51.89 34,832 1,807,432.48
    4.00 MRNA MODERNA INC United States BGSXTS3 26.86 65,832 1,768,247.52
    3.97 RARE ULTRAGENYX PHARM United States BJ62Z18 37.43 46,829 1,752,809.47
    3.86 LEGN LEGEND BIOTECH CORP-ADR United States BMX9K07 33.43 50,939 1,702,890.77
    3.85 RNA AVIDITY BIOSCIENCES INC United States BMWHPY1 29.90 56,949 1,702,775.10
    3.61 BNTX BIONTECH SE-ADR United States BK6H543 104.80 15,215 1,594,532.00
    3.58 VRTX VERTEX PHARM United States 2931034 445.82 3,548 1,581,769.36
    3.46 BMRN BIOMARIN PHARMAC United States 2437071 54.14 28,208 1,527,181.12
    2.86 WGS GENEDX HOLDINGS CORP United States BR841G5 88.93 14,209 1,263,606.37
    2.74 1548 HK GENSCRIPT BIOTECH CORP Hong Kong BD9Q2J2 1.91 636,118 1,212,270.74
    2.70 TWST TWIST BIOSCIENCE CORP United States BGKG6G7 36.99 32,212 1,191,521.88
    2.63 VCYT VERACYTE INC United States BFTWZY0 26.45 43,994 1,163,641.30
    2.31 ARWR ARROWHEAD PHARMA United States BYQBFJ8 15.66 65,210 1,021,188.60
    2.23 A AGILENT TECHNOLOGIES INC United States 2520153 118.62 8,295 983,952.90
    2.00 AZN LN ASTRAZENECA PLC United Kingdom 0989529 139.61 6,338 884,866.07
    1.96 GILD GILEAD SCIENCES INC United States 2369174 105.93 8,180 866,507.40
    1.90 BMY BRISTOL-MYERS SQUIBB CO United States 2126335 46.68 17,964 838,559.52
    1.88 LLY ELI LILLY & CO United States 2516152 792.30 1,051 832,707.30
    1.86 BEAM BEAM THERAPEUTICS INC United States BK6L288 16.76 49,064 822,312.64
    1.54 TXG 10X GENOMICS INC-CLASS A United States BKS3RS7 11.66 58,158 678,122.28
    1.28 CDNA CAREDX INC United States BP3YM74 19.11 29,492 563,592.12
    1.20 NTLA INTELLIA THERAPEUTICS INC United States BYZM6C2 9.56 55,601 531,545.56
    1.16 SRPT SAREPTA THERAPEUTICS INC United States B8DPDT7 17.46 29,369 512,782.74
    1.08 WVE WAVE LIFE SCIENCES LTD United States BYZG9R0 6.85 69,939 479,082.15
    1.06 PRAX PRAXIS PRECISION United States BQ721R4 43.33 10,762 466,317.46
    0.96 VERV VERVE THERAPEUTICS INC United States BNKGXX2 11.21 37,800 423,738.00
    0.92 QURE UNIQURE NV United States BJFSR88 14.33 28,225 404,464.25
    0.66 CVAC CUREVAC NV United States BN4RD42 5.44 53,503 291,056.32
    0.63 STOK STOKE THERAPEUTICS INC United States BJQ05Z6 11.81 23,726 280,204.06
    0.59 VIR VIR BIOTECHNOLOGY INC United States BK4PZ38 5.19 50,157 260,314.83
    0.58 MYGN MYRIAD GENETICS INC United States 2614153 5.12 50,179 256,916.48
    0.50 FLGT FULGENT GENETICS INC United States BYQBFQ5 19.57 11,308 221,297.56
    0.50 SANA SANA BIOTECHNOLOGY INC United States BMFJJ97 2.90 76,073 220,611.70
    0.50 RGNX REGENXBIO INC United States BZ0G875 8.54 25,735 219,776.90
    0.48 PSNL PERSONALIS INC United States BJQ0608 6.03 35,419 213,576.57
    0.44 ARCT ARCTURUS THERAPE United States BKC9SX3 13.95 13,873 193,528.35
    0.42 PACB PACIFIC BIOSCIEN United States B4N8MH9 1.22 150,268 183,326.96
    0.40 PRME PRIME MEDICINE INC United States BPBJFM7 2.42 72,897 176,410.74
    0.34 MRVI MARAVAI LIFESC-A United States BMCWKZ2 2.27 66,500 150,955.00
    0.34 RCKT ROCKET PHARMACEU United States BDFKQ07 2.65 56,476 149,661.40
    0.27 CRGX CARGO THERAPEUTICS INC United States BQHN2F2 4.14 28,545 118,176.30
    0.23 SGMO SANGAMO THERAPEUTICS INC United States 2573083 0.58 172,412 100,343.78
    0.23 ALLO ALLOGENE THERAPEUTICS INC United States BFZNYB7 1.24 80,629 99,979.96
    0.10 CASH United States 1.00 45,602 45,601.61
    -0.01 OTHER PAYABLE & RECEIVABLES United States 1.00 -2,697 -2,697.30
    Holdings are subject to change. "Cash" denotes U.S. dollars.

    Sector Breakdown As of 05/31/25

    Sector Weight (%)
    Health Care 100.0

    Source: AltaVista Research, LLC

    Country Breakdown As of 05/31/25

    Country Weight (%)
    United States 80.0
    Netherlands 5.4
    Germany 4.7
    Switzerland 4.1
    China 2.5
    Britain 2.2
    Singapore 1.1

    Source: AltaVista Research, LLC

    ETF Characteristics As of 06/25/25

    Return on Equity -30.00%
    Weighted Avg. Market Cap 15,996 M
    2024 2025
    Price-to-earnings -13.06 -13.70
    Price-to-book value 3.54 4.89

    Source: AltaVista Research, LLC

    ETF Risk Stats As of 05/31/25

    Versus Beta
    S&P 500 1.22
    MSCI EAFE 1.01
    MSCI Emg. Mkts 0.79
    Standard Deviation 28.70%

    Source: AltaVista Research, LLC

    ETF Documents

    TERMS OF USE

    Global X Brasil Gestora de Investimentos Ltda. (“Global X Brasil”) is an asset manager authorized by the Brazilian Securities and Exchange Commission (“CVM”), constituted in the form of CVM Resolution No. 21/2021. Investing involves risks. The material on this site is for informational purposes only and does not constitute investment advice, recommendation, offer or solicitation to buy or sell any securities, funds, or strategies to any person in any jurisdiction in which an offer, solicitation, purchase, or sale would be illegal under the securities laws of such jurisdiction. Opinions expressed here are subject to change without notice. Reliance upon the information contained in this material is at the sole discretion of the reader. No securities regulator has confirmed the accuracy of any information contained herein. Access to the information on this site or the use of the services or information provided herein is prohibited by any person or entity in any jurisdiction or country where such distribution or use is contrary to local law, rules, or regulation. Investment in index funds (ETFs) involves risks, including detachment from the benchmark index and related to the liquidity of shares in the secondary market. Investment funds managed by Global X Brasil use strategies that can result in significant equity losses for their quota holders. Global X Brasil, its partners and employees are exempt of responsibility for any damages resulting directly or indirectly from the use of the information contained on this website.

    FOR EVALUATION OF THE PERFORMANCE OF AN INVESTMENT FUND, IT IS RECOMMENDED THE ANALYSIS OF AT LEAST 12 (TWELVE) MONTHS. INVESTMENT FUNDS DO NOT HAVE A GUARANTEE FROM THE ADMINISTRATOR, THE MANAGER, ANY INSURANCE MECHANISM OR CREDIT GUARANTEE FUND – FGC. INVESTMENTS IN FINANCIAL AND CAPITAL MARKETS ARE SUBJECT TO RISKS OF LOSS GREATER THAN THE TOTAL VALUE OF INVESTED CAPITAL. PAST PROFITABILITY DOES NOT REPRESENT A GUARANTEE OF FUTURE PROFITABILITY THE PROFITABILITY DISCLOSED IS NOT NET OF TAXES. READ THE PROSPECTUS, THE FORM OF COMPLEMENTARY INFORMATION, SHEET OF ESSENTIAL INFORMATION AND THE REGULATION BEFORE INVESTING. DESCRIPTION OF THE ANBIMA TYPE AVAILABLE IN THE FORM OF COMPLEMENTARY INFORMATION.

    Back to Top